Drugs / Pegfilgrastim
Pegfilgrastim
also known as
Neulasta · PEG-rhG-CSF · Jinyouli · Peg GCSF · pegylated filgrastim · Pegylated recombinant human granulocyte colony-stimulating factor · Pegylated GCSF · Neulastim · +24 more
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | NEULASTA | — | 2005-09-15 – 2015-11-13 | fda.gov ↗ |
| Approved | EU (EMA) | Neulasta | — | 2002-08-22 | europa.eu ↗ |
| Approved | US (FDA) | NEULASTA | — | 2002-01-31 | fda.gov ↗ |
Trials 135 · started per year
today
US approved 2002
EU approved 2002
2
1
6
8
3
3
8
5
5
2
4
4
6
2
8
11
11
6
5
7
2
9
2
5
5
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05970185 | Feb → Apr 2024 | — | Zhongnan Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06168188 | Jul 2020 → Dec 2024 | optic nerve disorder | Buddhist Tzu Chi General Hospital | Unknown | No outcome recorded |
| Phase 123 trials | ||||||
| Phase 1 | NCT07416955 | Apr → Oct 2025 | — | Kashiv BioSciences, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04873765 | Mar → Aug 2022 | neutropenia | Megalabs | Completed | No outcome recorded |
| Phase 1 | NCT05222009 | Jan → Nov 2022 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1 | NCT04015232 | Feb → Jun 2018 | — | Intas Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04014062 | Feb → May 2018 | — | Intas Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03251248 | Aug 2017 → May 2018 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03251339 | Aug 2017 → Feb 2018 | — | Fresenius Kabi SwissBioSim GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03146988 | Apr → Sep 2017 | — | Gedeon Richter Plc. | Completed | No outcome recorded |
| Phase 1 | NCT03202927 | Mar 2017 → Mar 2018 | — | Adello Biologics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03206229 | Feb → Jun 2017 | — | Adello Biologics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02963389 | Oct 2016 → Nov 2018 | cancer, lymphoma | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02912377 | Sep 2016 → May 2017 | — | Cinfa Biotech | Completed | No outcome recorded |
| Phase 1 | NCT03376503 | May 2016 → Oct 2017 | breast cancer | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
| Phase 1 | NCT02589301 | Nov 2015 → Mar 2016 | neutropenia | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02629562 | Nov 2015 → Jul 2016 | — | Cinfa Biotech | Completed | No outcome recorded |
| Phase 1 | NCT02629289 | Aug 2015 → Jun 2016 | neutropenia | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02385851 | Feb → Jul 2015 | — | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02205320 | Feb → Aug 2014 | — | Dr. Reddy's Laboratories Limited | Unknown | No outcome recorded |
| Phase 1 | NCT01637493 | Feb 2012 → Feb 2013 | neutropenia | Hangzhou Jiuyuan Gene Engineering Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01037543 | Nov 2009 → Feb 2011 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT00969826 | Sep 2008 → Jan 2009 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00662519 | Apr 2008 → Mar 2014 | type 1 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT00959777 | — | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01106157 | Apr 2010 → Jan 2015 | type 1 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 1/2 | NCT01527422 | Jan 2006 → Nov 2010 | non-Hodgkin lymphoma | Fernando Cabanillas | Completed | No outcome recorded |
| Phase 246 trials | ||||||
| Phase 2 | NCT07188090 | Oct 2025 → Dec 2027 expected | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Thomas Jefferson University | Recruiting | No outcome recorded |
| Phase 2 | NCT06616987 | Jul 2025 → Jun 2027 expected | breast carcinoma | Yeon Hee Park | Recruiting | No outcome recorded |
| Phase 2 | NCT06135896 | Jan 2024 → Jun 2026 overdue | bile duct carcinoma, pancreas disorder | National Cancer Center, Korea | Recruiting | No outcome recorded |
| Phase 2 | NCT04477616 | Jul 2021 → Oct 2022 | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Completed | No outcome recorded |
| Phase 2 | NCT04547829 | Oct 2020 → Oct 2022 | childhood malignant neoplasm | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03993639 | May 2019 → Jul 2020 | disease related to hematopoietic stem cell transplant | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03571633 | Aug 2018 → Jan 2027 expected | HER2 positive breast carcinoma | Centre Leon Berard | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04542356 | Aug 2018 → Jan 2021 | cervical cancer | Chongqing University Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04227990 | Nov 2017 → Oct 2018 | neutropenia | BeyondSpring Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02776059 | Jan 2017 → Mar 2020 | alcoholic hepatitis | Timothy Morgan, MD | Completed | No outcome recorded |
| Phase 2 | NCT03575520 | Jun 2016 → Feb 2017 | breast cancer | Yonsei University | Completed | No outcome recorded |
| Phase 2 | NCT01918241 | Jul 2013 → Jan 2016 | neutropenia | Hangzhou Jiuyuan Gene Engineering Co. Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01724866 | Mar 2013 → Aug 2014 | neutropenia | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT01624805 | Jun 2012 → Jun 2029 expected | aplastic anemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT01923545 | Jul 2010 → May 2011 | neutropenia | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00856492 | Apr 2010 → Oct 2015 | breast cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00794261 | Sep 2008 → Jan 2010 | plasma cell myeloma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT00554463 | Jan 2008 → Aug 2011 | lung cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01682044 | Apr 2007 → Nov 2013 | MALT lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00478361 | Apr 2007 → Jun 2015 | bladder transitional cell carcinoma, renal pelvis/ureter urothelial carcinoma, urethra cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00470366 | Mar 2007 → Jun 2016 | central nervous system neoplasm, extragonadal germ cell tumor, ovarian cancer, teratoma +1 | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00410696 | Sep 2006 → Nov 2008 | hematopoietic and lymphoid cell neoplasm | Armando Santoro, MD | Completed | No outcome recorded |
| Phase 2 | NCT00364468 | Mar 2006 → Mar 2008 | neutropenia | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00526734 | Feb 2006 → ? | plasma cell myeloma | Erasme University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00306111 | Jan 2006 → Dec 2008 | non-Hodgkin lymphoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT02469116 | Jan 2006 → Aug 2009 | ovarian carcinoma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT00695370 | Jan 2006 → Dec 2007 | cancer | University Hospital, Clermont-Ferrand | Terminated | No outcome recorded |
| Phase 2 | NCT00107510 | Aug 2005 → Sep 2007 | breast cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00031629 | Jan 2005 → Jul 2007 | leiomyosarcoma of the corpus uteri | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00453232 | Aug 2004 → Dec 2008 | extragonadal germ cell tumor, teratoma, testicular germ cell tumor | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT00169143 | May 2004 → Jan 2007 | diffuse large B-cell lymphoma | Lymphoma Study Association | Completed | No outcome recorded |
| Phase 2 | NCT00726700 | May 2004 → Feb 2012 | lymphoma | Saarland University | Completed | No outcome recorded |
| Phase 2 | NCT00067639 | Dec 2003 → Apr 2007 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00101127 | Dec 2003 → Jul 2006 | sarcoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00682383 | Sep 2003 → Jan 2010 | non-small cell lung carcinoma | Mt. Sinai Medical Center, Miami | Completed | No outcome recorded |
| Phase 2 | NCT00146562 | Jul 2003 → May 2007 | breast cancer | Harold J. Burstein, MD, PhD | Completed | No outcome recorded |
| Phase 2 | NCT00066092 | Apr 2003 → Mar 2004 | Hodgkins lymphoma, non-Hodgkin lymphoma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00114764 | Mar 2003 → Apr 2004 | myeloid leukemia | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00117442 | Aug 2002 → Aug 2004 | breast cancer, lung cancer, ovarian cancer | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00117897 | Jul 2002 → Feb 2004 | non-Hodgkin lymphoma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00004192 | May 2000 → Feb 2001 | lymphoma, neutropenia | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT00035620 | Apr 2000 → Jan 2007 | neutropenia, sarcoma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00117455 | — | non-Hodgkin lymphoma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00115414 | — | female breast carcinoma, neutropenia | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00751894 | — | cancer | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT00124111 | — | breast cancer | Amgen | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01328938 | Oct 2010 → Nov 2012 | neutropenia | Green Cross Corporation | Completed | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT06711523 | Jan 2025 → Jun 2026 overdue | breast neoplasm, neutropenia | Kexing Biopharm Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06520163 | Aug 2024 → Aug 2026 overdue | non-Hodgkin lymphoma | The Affiliated People's Hospital of Ningbo University | Recruiting | No outcome recorded |
| Phase 3 | NCT06520176 | Aug 2024 → Dec 2026 expected | hemopoietic proliferation, plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Recruiting | No outcome recorded |
| Phase 3 | NCT06116734 | Nov 2023 → Nov 2024 | neutropenia, plasma cell myeloma | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 3 | NCT04466137 | Oct 2020 → Jun 2021 | neoplasm | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05283616 | May 2017 → Oct 2019 | neutropenia | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02953340 | May 2017 → Jun 2018 | breast cancer, neutropenia | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02761460 | May 2016 → Apr 2018 | breast cancer | wang shusen | Unknown | No outcome recorded |
| Phase 3 | NCT02643420 | Jan 2016 → Jan 2018 | breast cancer, neutropenia | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT03404752 | Aug 2015 → Jun 2018 | breast cancer | Gema Biotech S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT02238873 | Oct 2014 → Jan 2018 | lymphoma, neutropenia | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01674855 | Feb 2012 → Feb 2013 | neutropenia | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00536081 | Jan 2008 → Dec 2009 | breast cancer | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00516425 | Jan 2007 → ? | female breast carcinoma | Charing Cross Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00301925 | Dec 2005 → Sep 2024 | breast cancer | Institute of Cancer Research, United Kingdom | Unknown | No outcome recorded |
| Phase 3 | NCT00433420 | Apr 2003 → May 2006 overdue | breast cancer | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00117910 | Oct 2002 → May 2004 | breast cancer | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00035594 | Feb 2002 → Feb 2004 | neutropenia | Amgen | Completed | No outcome recorded |
| Phase 423 trials | ||||||
| Phase 4 | NCT06616571 | Sep 2024 → Dec 2025 overdue | chemotherapy-induced toxicity | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 4 | NCT05409547 | Jun 2022 → Apr 2025 | hemopoietic proliferation | Ning Huang | Unknown | No outcome recorded |
| Phase 4 | NCT06026995 | Mar 2022 → Jan 2024 | lymphoma | Chongqing University Cancer Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04009941 | Aug 2019 → Jan 2020 | breast cancer, neutropenia | Peking University | Completed | No outcome recorded |
| Phase 4 | NCT04083079 | Aug 2019 → Aug 2021 | non-Hodgkin lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03511378 | Mar 2018 → Jan 2019 | breast cancer | Lupin Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03858166 | Dec 2017 → Dec 2020 | ovarian cancer | Shandong University | Terminated | No outcome recorded |
| Phase 4 | NCT03206684 | Aug 2017 → Jul 2018 | cervical cancer | Air Force Military Medical University, China | Unknown | No outcome recorded |
| Phase 4 | NCT02996617 | Nov 2016 → Nov 2018 | non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02944604 | Sep 2016 → Sep 2017 | breast cancer | Peking University | Completed | No outcome recorded |
| Phase 4 | NCT02905916 | Jun 2016 → Jun 2018 | bone neoplasm, breast cancer, female reproductive system neoplasm, lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT03844360 | Jan 2016 → Dec 2025 overdue | hematopoietic and lymphoid cell neoplasm | Wei Zhao | Recruiting | No outcome recorded |
| Phase 4 | NCT02905942 | Dec 2015 → Dec 2018 | lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02953730 | Sep 2015 → Jun 2016 | acute lymphoblastic leukemia | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02441894 | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02805218 | Sep 2013 → Feb 2016 | lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02805166 | Apr 2013 → Feb 2016 | cancer | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02805205 | Apr 2013 → Feb 2016 | breast cancer | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02805153 | Apr 2013 → Feb 2016 | breast cancer | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02782845 | Jun 2006 → Oct 2007 | non-Hodgkin lymphoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00115206 | Jul 2002 → Jul 2004 | non-small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00277160 | Jun 2002 → Nov 2004 | breast cancer, lung cancer, neutropenia, non-Hodgkin lymphoma +1 | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00030758 | Oct 2001 → ? | breast cancer, neutropenia | Anglo Celtic Cooperative Oncology Group | Unknown | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT07525869 | Oct 2025 → Oct 2026 expected | triple-negative breast carcinoma | Yonsei University | Recruiting | No outcome recorded |
| — | NCT05834751 | May 2023 → May 2025 | lymphoma | Ou Bai, MD/PHD | Unknown | No outcome recorded |
| — | NCT05536154 | Nov 2022 → Jun 2024 | plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Unknown | No outcome recorded |
| — | NCT05296317 | Sep 2022 → Sep 2025 | breast carcinoma | Centre Georges Francois Leclerc | Completed | No outcome recorded |
| — | NCT05510089 | Sep 2022 → May 2024 | hematopoietic and lymphoid cell neoplasm | The Affiliated People's Hospital of Ningbo University | Unknown | No outcome recorded |
| — | NCT05531279 | Jun 2022 → Jun 2025 | aplastic anemia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| — | NCT06060080 | Apr 2022 → Dec 2023 | plasma cell myeloma | Yao Liu | Unknown | No outcome recorded |
| — | NCT05156554 | Dec 2021 → Dec 2022 | lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT04518800 | Aug 2020 → Aug 2021 | malignant pancreatic neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT04497701 | Aug 2020 → Aug 2021 | leukemia, lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04500886 | Aug 2020 → Aug 2021 | hemophagocytic syndrome | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04239001 | Feb → Dec 2020 | pancreatic neoplasm | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT03870412 | Feb 2019 → Mar 2021 | adult lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04497688 | Jan 2019 → Sep 2020 | non-Hodgkin lymphoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT03776604 | Dec 2018 → Dec 2019 | small cell lung carcinoma | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT02788240 | May 2016 → Jul 2017 | liver failure | Institute of Liver and Biliary Sciences, India | Terminated | No outcome recorded |
| — | NCT01541072 | Feb 2012 → Jun 2014 | B-cell non-Hodgkin lymphoma | Centre Leon Berard | Terminated | No outcome recorded |
| — | NCT00886509 | Mar 2009 → Feb 2015 | coronary artery disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| — | NCT00689884 | Jan 2007 → Jan 2009 | hematopoietic and lymphoid cell neoplasm | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| — | NCT00283621 | Jun 2003 → Apr 2006 | sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 248 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02392039 Background | Dec 2015 → Apr 2018 | lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT00515138 Background | May 2007 → Nov 2011 | B-cell non-Hodgkin lymphoma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 139 trials | ||||||
| Phase 1 | NCT07278856 Background | Dec 2025 → Mar 2027 expected | Nodal T-follicular helper cell lymphoma, follicular type, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06698861 Comparator | Aug 2024 → Feb 2025 | — | PharmaEssentia | Completed | No outcome recorded |
| Phase 1 | NCT05211336 Background | Apr 2022 → Jun 2024 overdue | diffuse large B-cell lymphoma of the central nervous system | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04762901 Background | Apr 2021 → Jan 2026 | breast cancer | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 1 | NCT04661852 Background | Dec 2020 → Oct 2022 | Ewing sarcoma, osteosarcoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT04651036 Comparator | Nov 2020 → Nov 2021 | — | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04584112 Background | Sep 2020 → Mar 2023 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04323956 Background | Jun 2020 → Oct 2023 overdue | diffuse large B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, marginal zone lymphoma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04156828 Background | Mar 2020 → Apr 2022 | diffuse large B-cell lymphoma, follicular lymphoma | University of Washington | Terminated | No outcome recorded |
| Phase 1 | NCT04023669 Background | Aug 2019 → May 2023 | brain cancer, medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4 | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03220022 Background | Mar 2018 → Oct 2024 overdue | diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03273842 Comparator | Oct 2017 → Jul 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03107988 Background | Sep 2017 → Aug 2024 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Completed | No outcome recorded |
| Phase 1 | NCT02943733 Background | Aug 2017 → Nov 2020 | cancer, neuroendocrine neoplasm | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1 | NCT02909036 Background | Sep 2016 → Sep 2026 expected | amyloidosis, plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02728531 Background | Apr 2016 → Jan 2019 | mantle cell lymphoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02649673 Background | Mar 2016 → Jul 2021 | ovarian carcinoma, small cell lung carcinoma | SCRI Development Innovations, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT02650635 Background | Feb → Sep 2016 | breast carcinoma, colorectal adenocarcinoma, cutaneous melanoma, non-small cell lung carcinoma +2 | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT02592395 Background | Oct 2015 → Oct 2017 | pancreatic adenocarcinoma | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded |
| Phase 1 | NCT02418104 Comparator | May → Dec 2015 | — | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02392793 Comparator | Mar 2015 → Feb 2019 | childhood malignant neoplasm | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02181218 Background | Feb 2015 → Mar 2019 | Hodgkins lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02390843 Background | Feb 2015 → Sep 2019 | Ewing sarcoma, Wilms tumor, clear cell sarcoma, germ cell tumor +7 | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01840566 Background | Apr 2013 → Apr 2027 expected | non-Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01654965 Background | Jul 2012 → Mar 2018 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01594918 Background | Jun 2012 → Aug 2016 | prostate carcinoma | Rahul Aggarwal | Completed | No outcome recorded |
| Phase 1 | NCT01491841 Background | Nov 2011 → Nov 2016 | non-Hodgkin lymphoma | Anne Beaven, MD | Completed | No outcome recorded |
| Phase 1 | NCT01446458 Background | Nov 2011 → Mar 2015 | malignant pancreatic neoplasm | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01385228 Background | Jun 2011 → Jul 2015 | prostate cancer | Daniel George, MD | Completed | No outcome recorded |
| Phase 1 | NCT01258634 Background | Jul 2010 → Nov 2011 | osteosarcoma, respiratory system cancer | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT00938678 Comparator | Jun → Oct 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00787969 Background | Apr 2009 → Apr 2012 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1 | NCT01214642 Background | May 2008 → Dec 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00575952 Background | Jan 2008 → Jul 2016 | endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial mixed adenocarcinoma, endometrial serous adenocarcinoma +1 | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT01214629 Background | Jul 2007 → May 2012 | cancer of unknown primary site, metastatic malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00352300 Background | Jun 2006 → Jul 2010 | fallopian tube carcinoma, infectious disease, neutropenia, ovarian carcinosarcoma +1 | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT00346229 Background | Apr 2006 → Apr 2011 | breast cancer | Duke University | Terminated | No outcome recorded |
| Phase 1 | NCT00612989 Background | Feb 2005 → Aug 2007 | gliosarcoma | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT00075634 Background | Dec 2003 → Sep 2007 | childhood malignant neoplasm, neuroblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/228 trials | ||||||
| Phase 1/2 | NCT07064018 Background | Apr 2025 → Dec 2029 expected | cervical cancer, non-small cell lung carcinoma, ovarian cancer, soft tissue sarcoma +1 | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06709495 Background | Jan 2025 → Nov 2028 expected | Ewing sarcoma, desmoplastic small round cell tumor, osteosarcoma, rhabdomyosarcoma | David S Shulman, MD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05634369 Background | Nov 2022 → Dec 2026 expected | sarcoma | Nationwide Children's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05032183 Background | Feb 2022 → Jul 2024 | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT05011188 Background | Jan 2022 → Jul 2027 expected | prostate carcinoma | Rahul Aggarwal | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03214562 Background | Sep 2017 → Sep 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02834403 Background | Nov 2016 → Jan 2021 | triple-negative breast carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02431403 Background | Feb 2015 → Feb 2020 | non-Hodgkin lymphoma | Pusan National University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02073097 Background | Jan 2015 → Jul 2021 | diffuse large B-cell lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02142049 Background | May 2014 → Aug 2017 | diffuse large B-cell lymphoma | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 1/2 | NCT01879085 Background | Sep 2013 → Apr 2021 | sarcoma | Melissa Burgess, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01657331 Background | Jul 2012 → Jun 2018 | Hodgkins lymphoma, anaplastic large cell lymphoma | Columbia University | Completed | No outcome recorded |
| Phase 1/2 | NCT01355705 Background | Aug 2011 → Jul 2016 | plasma cell myeloma | Michaela Liedtke | Completed | No outcome recorded |
| Phase 1/2 | NCT01169636 Background | Jan 2011 → May 2017 | Hodgkins lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02983097 Background | Nov 2010 → Jan 2014 | Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Terminated | No outcome recorded |
| Phase 1/2 | NCT00968253 Background | Nov 2009 → Dec 2015 | acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00670358 Background | Aug 2008 → May 2021 | lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00667615 Background | Apr 2008 → Feb 2017 | Hodgkins lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00645333 Background | Mar 2008 → Jan 2010 | breast cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00472849 Background | May 2007 → Feb 2012 | Richter transformation, leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00503984 Background | May 2007 → Jun 2015 | prostate cancer | University of Miami | Terminated | No outcome recorded |
| Phase 1/2 | NCT00551122 Background | Nov 2006 → Apr 2013 | central nervous system neoplasm, extragonadal germ cell tumor, ovarian cancer, testicular germ cell tumor | University of Southampton | Unknown | No outcome recorded |
| Phase 1/2 | NCT00546377 Background | Jul 2005 → May 2014 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00217529 Background | Jun 2004 → Nov 2005 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00086944 Background | May 2004 → Jul 2006 | diffuse large B-cell lymphoma, mantle cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00066443 Background | Nov 2003 → Jan 2010 | breast cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00077103 Background | Nov 2003 → Feb 2007 | head and neck cancer | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00063934 Background | May 2003 → Feb 2008 | male breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2117 trials | ||||||
| Phase 2 | NCT07059611 Background | Sep 2026 → Nov 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07021989 Background | Jul 2026 → May 2029 expected | classic Hodgkin lymphoma | Michael Spinner, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06738368 Background | May 2026 → Jan 2028 expected | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06528691 Background | May 2026 → Nov 2027 expected | central nervous system neoplasm, glioma | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07224100 Background | Mar 2026 → Jul 2028 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), lymphoblastic lymphoma | University of Washington | Recruiting | No outcome recorded |
| Show all 117 trials opens the full record — a long page | ||||||
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT05870748 Background | Jul 2023 → Aug 2025 | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sutro Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT04628767 Background | Nov 2021 → Sep 2027 expected | renal pelvis/ureter urothelial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04554056 Comparator | Sep 2020 → Aug 2022 | female breast carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT01805557 Background | Feb 2013 → Mar 2019 | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 2/3 | NCT01046825 Background | Sep 2010 → Aug 2023 overdue | neoplasm of mature B-cells | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01057069 Comparator | Jan 2010 → Jun 2023 overdue | breast cancer | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00837265 Comparator | Aug 2008 → Jun 2009 | neutropenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00151242 Background | Jul 2004 → Aug 2011 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 343 trials | ||||||
| Phase 3 | NCT07419295 Background | Apr 2026 → Jul 2029 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06220032 Background | Aug 2024 → Dec 2028 expected | diffuse large B-cell lymphoma | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT06212752 Background | Jun 2023 → Nov 2024 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05722015 Background | Feb 2023 → Jul 2024 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04685616 Background | Apr 2022 → Sep 2030 expected | Hodgkins lymphoma | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT06188676 Background | Apr 2022 → Apr 2029 expected | mediastinal malignant lymphoma | National Research Center for Hematology, Russia | Recruiting | No outcome recorded |
| Phase 3 | NCT04759586 Background | Oct 2021 → Dec 2026 expected | primary mediastinal large B-cell lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03294577 Comparator | Oct 2019 → Sep 2020 | neutropenia | BeyondSpring Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT03907488 Background | Aug 2019 → Mar 2024 overdue | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03731442 Background | Nov 2018 → Oct 2022 overdue | esophageal cancer | Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 3 | NCT03102606 Comparator | May → Dec 2018 | neutropenia | BeyondSpring Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03252431 Comparator | Apr 2018 → Sep 2019 | female breast carcinoma, neutropenia | EVIVE Biotechnology | Completed | No outcome recorded |
| Phase 3 | NCT02768714 Comparator | Jan 2018 → Oct 2019 | breast cancer | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT03197935 Background | Jul 2017 → Apr 2020 | triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02810743 Comparator | Jan 2017 → Jul 2024 overdue | breast cancer | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03381417 Comparator | Oct 2016 → Nov 2017 | female breast carcinoma | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
| Phase 3 | NCT02375204 Background | Aug 2015 → Jun 2031 expected | choriocarcinoma, extragonadal seminoma, germinoma, mixed germ cell tumor +2 | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02467868 Comparator | Mar → Sep 2015 | breast cancer, chemotherapy-induced toxicity | Mylan Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02044276 Comparator | Mar 2014 → Aug 2017 | aggressive B-cell non-Hodgkin lymphoma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02582697 Background | Feb 2014 → Dec 2029 expected | germ cell tumor | University of Sydney | Recruiting | No outcome recorded |
| Phase 3 | NCT01933932 Background | Sep 2013 → Jun 2016 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01533207 Background | Jun 2012 → Jun 2018 | leiomyosarcoma of the corpus uteri | Gynecologic Oncology Group | Terminated | No outcome recorded |
| Phase 3 | NCT01735175 Comparator | Jun 2012 → May 2013 | breast cancer, chemotherapy-induced toxicity, neutropenia | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT01126190 Comparator | Jun 2010 → Feb 2012 | neutropenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00893399 Background | May 2010 → Sep 2021 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT00911170 Comparator | Nov 2009 → Sep 2012 | colon carcinoma, neutropenia, rectal cancer | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01012297 Background | Nov 2009 → Sep 2015 | leiomyosarcoma of the corpus uteri | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT00887536 Comparator | May 2009 → Feb 2018 | breast cancer | NSABP Foundation Inc | Completed | No outcome recorded |
| Phase 3 | NCT00678327 Background | Aug 2008 → Jan 2016 | lymphoma | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT01985724 Background | Oct 2007 → Dec 2013 | breast cancer | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00304070 Background | May 2007 → Dec 2015 | adrenal cortex carcinoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00574080 Background | Jul 2006 → Mar 2011 | plasma cell myeloma | University of Arkansas | Terminated | No outcome recorded |
| Phase 3 | NCT01285219 Comparator | Jan 2006 → May 2007 | cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00499018 Background | Jan 2006 → Jun 2011 | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Unknown | No outcome recorded |
| Phase 3 | NCT00118209 Comparator | May 2005 → Oct 2017 | large B-cell lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00113386 Background | Apr 2005 → Feb 2009 | lung cancer | Radiation Therapy Oncology Group | Terminated | No outcome recorded |
| Phase 3 | NCT00615602 Background | Oct 2004 → May 2012 | female breast carcinoma | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00431080 Background | Aug 2004 → Oct 2007 | breast cancer | Hellenic Oncology Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00070564 Background | Nov 2003 → Jan 2015 overdue | breast cancer | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00063999 Comparator | Aug 2003 → Jun 2013 | uterine corpus cancer | GOG Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00061984 Background | Apr 2003 → May 2010 | sarcoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00049595 Background | Aug 2002 → Jan 2010 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00006011 Background | Jul 2000 → Mar 2010 | endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05753618 Comparator | Apr 2023 → Oct 2026 expected | breast cancer | Ottawa Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT04781959 Comparator | Jun 2021 → Feb 2023 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01501487 Comparator | Oct 2011 → Feb 2016 | breast cancer | Agendia | Completed | No outcome recorded |
| Phase 4 | NCT00466258 Background | Oct 2006 → May 2009 | HIV infectious disease, diffuse large B-cell lymphoma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT00675597 Background | May 2008 → Feb 2012 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00615901 Background | Jan 2008 → Jun 2010 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00436709 Background | Jul 2006 → ? | breast cancer | Memorial Sloan Kettering Cancer Center | Unknown | No outcome recorded |
| — | NCT00346125 Comparator | Apr 2006 → Jul 2013 | sarcoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| — | NCT00310089 Background | Jan 2006 → Jul 2007 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00617370 Background | Nov 2004 → Jul 2005 | breast adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03649438 Background | — | neuroblastoma, pheochromocytoma | University of Texas Southwestern Medical Center | No longer available | No outcome recorded |
Press releases naming this drug 13 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-11 | Pfizer | FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf) pfizer.com ↗ |
| 2019-11-05 | Novartis Pharmaceuticals | Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez) novartis.com ↗ |
| 2019-04-03 | Novartis Pharmaceuticals | Sandoz resubmits biosimilar pegfilgrastim application to US FDA novartis.com ↗ |
| 2018-11-27 | Novartis Pharmaceuticals | Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim) novartis.com ↗ |
| 2018-09-21 | Novartis Pharmaceuticals | Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim novartis.com ↗ |
| 2018-02-27 | Amgen | Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim) amgen.com ↗ |
| 2017-12-08 | Novartis Pharmaceuticals | Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine novartis.com ↗ |
| 2017-10-27 | Novartis Pharmaceuticals | Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review novartis.com ↗ |
| 2017-04-18 | Amgen | Amgen Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES amgen.com ↗ |
| 2016-02-11 | Novartis Pharmaceuticals | Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim novartis.com ↗ |
| 2015-12-07 | Novartis Pharmaceuticals | Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product novartis.com ↗ |
| 2015-11-18 | Novartis Pharmaceuticals | Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA novartis.com ↗ |
| 2015-03-02 | Amgen | Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit amgen.com ↗ |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 386 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegfilgrastim | “The study was an assessor-blind, balanced, randomized, two-treatment, two-period, single-dose, two-way crossover, comparative, pharmacokinetic (PK) and pharmacodynamic (PD)...” NCT04014062 ↗290“Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting...” NCT00211185 ↗ “Participants randomized to this arm will receive abiraterone acetate (1000 mg/day), prednisone (5 mg twice daily), leuprolide (22.5 mg every 3 months), and cabazitaxel (20...” NCT02543255 ↗ “Recommended rescue medications are pegfilgrastim or equivalent, histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent,...” NCT07419295 ↗ “PEG-Filgrastim would be given in order to allow us to administer the chemotherapy courses every 2 weeks with the practical advantage of requiring only one dose of...” NCT01527422 ↗ “patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.” NCT02805153 ↗ “Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan.” NCT02649673 ↗ “Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.” NCT01057069 ↗ “The aim of this trial was to determine the safety and efficacy of pegfilgrastim, a long-acting recombinant GCSF, in patients with AH in the United States.” PMID 36267499 ↗ Oct 2022 “All patients will receive G-CSF (peg-filgrastim or filgrastim) starting on day -4, prior to planned peripheral blood stem cell collection on day 0.” NCT07188090 ↗ “Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.” NCT00968253 ↗ “Participants will also receive pegfilgrastim or G-CSF (growth stimulating colony factor) to help with rapid recovery of the normal bone marrow” NCT00669877 ↗ “Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer” PMID 24821883 ↗ May 2014 “Neulasta Administration. Neulasta administered by subcutaneous injection in 0.6mL pre-filled syringe containing 6mg of pegfilgrastim.” NCT00612989 ↗ “Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.” NCT05753618 ↗ “All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.” NCT00944047 ↗ “The names of the non-investigational supportive care drugs are: * Filgrastim, pegfilgrastim, or a related growth factor.” NCT04661852 ↗ “Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8” NCT01782339 ↗ “Pegfilgrastim (Neulasta) fixed dose of 6 mg (0.6 mL of a 10 mg/mL solution) as a single subcutaneous injection” NCT00256360 ↗ “Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF).” NCT02087176 ↗ “Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults” NCT07416955 ↗ “Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.” NCT00189137 ↗ “Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide” NCT02790580 ↗ “a biosimilar pegfilgrastim (B12019) and the reference product Neulasta® in healthy subjects” NCT02912377 ↗ “Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim” NCT02142049 ↗ “In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted.” NCT01046825 ↗ “supported by 6 mg prophylactic pegfilgrastim subcutaneously every 2 weeks” PMID 42372741 ↗ Jul 2026 “Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose” NCT04873765 ↗ “Biosimilar Pegfilgrastim (B12019) Versus the Reference Product Neulasta®” NCT02629562 ↗ “Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy” NCT02374424 ↗ “They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6” NCT00515138 ↗ “6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection” NCT04477616 ↗ “Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy” NCT01805557 ↗ “Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle.” NCT02685111 ↗ “PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta®).” PMID 32524499 ↗ Jun 2020 “Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection” NCT00286819 ↗ “Pegfilgrastim (Peg-GCSF) 0.1mg/kg/dose (max 6 mg/dose) SQ on Day 9” NCT05634369 ↗ “Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia” NCT01701076 ↗ “Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim” NCT00893399 ↗ “Pegfilgrastim 6 mg SQ injection day 2 of each cycle” NCT00682383 ↗ “GCPGC ia a solution for containing pegfilgrastim.” NCT01328938 ↗ “INTP5, a pegfilgrastim biosimilar to US Neulasta.” NCT04015232 ↗ “or single dose of peg-filgrastim on days 2 \& 16” NCT04685616 ↗ “Biosimilar pegfilgrastim or Lapelga™ (one dose)” NCT06116734 ↗ “a single dose of 6 mg pegfilgrastim (Neulasta)” NCT06698861 ↗ “with pegfilgrastim SQ day # 2 (6 mg)” NCT00617370 ↗ “RGB-02 or Neulasta® (pegfilgrastim)” NCT03146988 ↗ “pegfilgrastim 6 mg sq on day 2-3” NCT01501487 ↗ “and pegfilgrastim 6mg on day 6.” NCT04687098 ↗ “Neulasta® (pegfilgrastim)” NCT06168188 ↗ “filgrastim, pegfilgrastim” NCT04584112 ↗ “Drug: Peg-filgrastim” NCT02685111 ↗ “Pegfilgrastim 6 mg” NCT01933932 ↗ “Pegfilgrastim 6mg” NCT02431403 ↗ “Pegfilgrastim” NCT00466258 ↗ “pegfilgrastim” NCT03646123 ↗ |
| Known as | B12019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02629562 ↗ |
| Known as | biosimilar pegfilgrastim | “biosimilar pegfilgrastim” NCT06116734 ↗ |
| Known as | DA-3031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00959777 ↗ |
| Known as | Granulocyte-colony stimulating growth factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00615602 ↗ |
| Known as | Jinyouli | “Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to...” NCT03870412 ↗6“Patients received subcutaneous injection of PEG-rhG-CSF(Jinyouli®) 48 hours after the end of chemotherapy, 6mg for patients with body weight≥45kg and 3mg for patients with body...” NCT04497688 ↗ “A Single-center, Open-label, Controlled Clinical Study to Evaluate the Efficacy and Safety of Jinyouli®(PEG-rhG-CSF) for the Recovery of Neutropenia After Chemotherapy in...” NCT04500886 ↗ “Jin Youli(PEG-rhG-CSF): jinyouli injection was given 24 hours after the completion of intravenous infusion of albumin paclitaxel during the treatment period” NCT04239001 ↗ “Patients received a single dose of 100 ug/kg of PEG-rhG-CSF（Jinyouli®）, on the basis of actual body weight.” NCT04497701 ↗ “Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight.” NCT03776604 ↗ |
| Known as | KRN125 | “Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients” NCT00364468 ↗1“after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.” NCT03993639 ↗ |
| Known as | Lapelga | “Biosimilar pegfilgrastim or Lapelga™ (one dose)” NCT06116734 ↗ |
| Known as | mecapegfilgrastim | “polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF; mecapegfilgrastim) has been developed.” PMID 41510127 ↗ Dec 2025 |
| Known as | Nanogen pegfilgrastim | “Pegcyte (Nanogen pegfilgrastim)” NCT03376503 ↗ |
| Known as | Neulasta | “Single subcutaneous injection of 6 mg PEG-G-CSF injection ( Neulasta®, Amgen Europe B.V.) 24h+2h after the end of chemotherapy administration on day 1 of each chemotherapy...” NCT06711523 ↗49“Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.” NCT01750866 ↗ “Pegfilgrastim (Neulasta) fixed dose of 6mg (0.6mL of a 10mg/mL solution) as a single subcutaneous injection on Day 2 of each study cycle.” NCT00291850 ↗ “Pegfilgrastim (Neulasta) fixed dose of 6 mg (0.6 mL of a 10 mg/mL solution) as a single subcutaneous injection” NCT00256360 ↗ “compared with Neulasta® (pegfilgrastim) in women with breast cancer who are receiving myelotoxic chemotherapy.” NCT01648322 ↗ “It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment” NCT02578732 ↗ “Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5” NCT00794261 ↗ “ASCT,Rituxan, Ifex, Paraplatin®, etoposide, Vepesid®, Mesnex®, Neupogen, Neulasta” NCT00588094 ↗ “or receive equivalent single dose of Neulasta every 14 days while neutropenic” NCT03649438 ↗ “Mobilization: one sc injection of 300 µg/kg pegfilgrastim (Neulasta, Amgen)” NCT00695370 ↗ “pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3” NCT01446458 ↗ “Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA” NCT03206229 ↗ “Neulasta injection 6mg subcutaneous” NCT02592395 ↗ “Neulasta 6mg SQ will also be given” NCT01125787 ↗ “Pegfilgrastim (Neulasta, Amgen)” NCT00751894 ↗ “neulasta 6 mg Day 2, 16, 30, 44” NCT00232479 ↗ “Neulasta (pegfilgrastim) 6mg” NCT01328938 ↗ “with Neulasta or equivalent” NCT04506554 ↗ “Neulasta® (pegfilgrastim)” NCT00115206 ↗ “pegfilgrastim (Neulasta®)” NCT00887536 ↗ “Pegfilgrastim (Neulasta)” NCT07525869 ↗ “Neulasta (pegfilgrastim)” NCT00283621 ↗ “Neulasta (pegfilgrastim)” NCT00277160 ↗ “Pegfilgrastim (Neulasta)” NCT00067639 ↗ “Neulasta” NCT00431080 ↗ |
| Known as | Neulasta(r) | “Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.” NCT01057069 ↗ |
| Known as | Neulastim | “An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)” NCT02782845 ↗ |
| Known as | Peg Filgrastim[Neulasta (G-CSF or GCSF)] | “Peg Filgrastim[Neulasta (G-CSF or GCSF)]” NCT01527422 ↗ |
| Known as | Peg GCSF | “At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per...” NCT02042391 ↗ |
| Known as | PEG-rhG-CSF | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 202539“Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is rhG-CSF chemically modified by a single methoxy polyethylene glycol group; it is able to...” NCT02996617 ↗ “Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can be used in pediatric patients.” PMID 37183837 ↗ May 2023 “6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection” NCT04477616 ↗ “Jin Youli(PEG-rhG-CSF)” NCT04518800 ↗ “QL0605(PEG-rhG-CSF)” NCT06616571 ↗ |
| Known as | PEG-rhG-CSF injection | “PEG-rhG-CSF injection” NCT04554056 ↗ |
| Known as | Pegcyte | “Pegcyte (Nanogen pegfilgrastim)” NCT03376503 ↗ |
| Known as | Pegfilgastim Amgen | “Biological: Pegfilgastim Amgen” NCT04873765 ↗ |
| Known as | Pegfilgastrim Megalabs | “Biological: Pegfilgastrim Megalabs” NCT04873765 ↗ |
| Known as | Pegfilgrastim Amgen | “Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose” NCT04873765 ↗ |
| Known as | Pegfilgrastim Megalabs | “Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose” NCT04873765 ↗ |
| Known as | pegylated filgrastim | “Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous...” NCT01446458 ↗6“DA-3031 is a newly developed pegylated filgrastim, a recombinant human granulocyte colony-stimulating factor, that is expected to have an extended duration of action compared...” PMID 24078278 ↗ Nov 2013 “followed by pegylated filgrastim 6mg subcutaneously on day 2” NCT00675597 ↗ “Filgrastim or pegylated filgrastim” NCT00953420 ↗ |
| Known as | Pegylated GCSF | “Myeloid growth factor (G-CSF or pegylated G-CSF)” NCT02390843 ↗ |
| Known as | Pegylated recombinant human granulocyte colony-stimulating factor | “Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is rhG-CSF chemically modified by a single methoxy polyethylene glycol group; it is able to...” NCT02996617 ↗5“Pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF) is a first class national new drug developed by domestic pharmaceutical companies.” NCT02761460 ↗ “pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF)” NCT05409547 ↗ “PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)” NCT02944604 ↗ |
| Known as | Pegylated Recombinant Human Granulocyte Stimulating Factor | “The purpose of the trail is to study the pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents” NCT02953730 ↗1“Jinyouli (PEGylated Recombinant Human Granulocyte Stimulating Factor, PEG-rhG-CSF)” NCT03776604 ↗ |
| Known as | pegylated rhG-CSF | “Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle” NCT02996617 ↗ |
| Known as | QL0605 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06616571 ↗ |
| Known as | Roche pegfilgrastim | “Neulastim (Roche pegfilgrastim)” NCT03376503 ↗ |
| Known as | TPI-120 | “Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults” NCT07416955 ↗1“TPI-120 (PEGFILGRASTIM)” NCT03202927 ↗ |
| Known as | Tripegfilgrastim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02963389 ↗ |
| Known as | US-Neulasta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03251339 ↗ |
| Known as | Xinruibai | “Patients with NSCLC who received 1-4 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2 mg, 33 µg/kg or control drug (rhG-CSF...” PMID 40098083 ↗ Mar 2025 |
| Action | Activate | “Colony-stimulating factor” NCT02834403 ↗ |
| Modality | Protein / enzyme biologic | “Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.” NCT00035594 ↗ |
| Route | Subcutaneous | “Alternatively, patients may receive pegfilgrastim SC beginning 24-36 hours after completion of each course of chemotherapy and continuing until blood counts recover.” NCT00003955 ↗ |